Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression

Journal of Rheumatology

Volumn 27, Issue 12, 2000, Pages 2761-2768

  Posthumus, M D ^a   Limburg, P C ^a   Westra, J ^a   Van Leeuwen, M A ^a   Van Rijswijk, M H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Disease activity; Early rheumatoid arthritis; Radiological damage; Serum matrix metalloproteinase 3; Stromelysin 1

Indexed keywords

C REACTIVE PROTEIN; STROMELYSIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT CAVITY; JOINT RADIOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0033663810     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants
2. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease
3. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients
4. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression
5. Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: A reflection of local or systemic inflammation?
6. Increased serum pro-MMP-3 in inflammatory arthritides: A potential indicator of synovial inflammatory monokine activity
7. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis
8. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis
9. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis
10. Proteinases and matrix degradation
11. Susceptibility of stromelysin 1-deficient mice to collagen induced arthritis and cartilage destruction
12. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis
13. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage
14. Activation mechanisms of matrix metalloproteinases
15. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium
16. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): Correlation with rheumatoid arthritis
17. Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro
18. Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs
19. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis
20. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis
21. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury
22. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis
23. Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay
24. Alpha 2-macroglobulin
25. Elevated plasma stromelysin levels in arthritis
26. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis
27. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis
28. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
29. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis
30. Early rheumatoid arthritis: Time to aim for remission?
31. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
32. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
33. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
34. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
35. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)
36. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies
37. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity
38. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate
39. CRP measurements in rheumatic disorders
40. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?
41. Analysis of serial measurements in medical research
42. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation
43. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
44. Serum MMP-3 in rheumatoid arthritis: Correlation with systemic inflammation but not with erosive status
45. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system